MS patients have a generally increased risk of cardiovascular disease, but there is little data on how different disease modifying treatments may alter this risk in patients treated in clinical practice. In this MEDtalk Thomas Frisell ...

In this MEDtalk Nasrin Asgari present an experimental model of neuromyelitis optica spectrum disorder. The model mimicks human disease ...

Asta Theodorsdottir prsent data from the The Danish Multiple Sclerosis Registry about the demographics of the alemtuzumab-treated population in Denmark; the treatment strategy; the number of cycles and its relation to previous disease modifying treatments (DMTs); and the frequency of switch to other ...

In this MEDtalk Tone Berge present new insights into immune-cell processes in MS through evaluate dysregulation af CD4+ and CD8+ cells from MS ...

Smoking, air pollution and MS

ECTRIMS 2019 | BestPractice | 13. Septt 2019 kl. 3:47 |

Hear the latest data on the association between smoking and an increased risk of MS. There are several interesting new ...

Sporadic cases of fatal adverse events have been reported during treatment of multiple sclerosis with alemtuzumab. In this MEDtalk Trygve Holmøy present a study based on European Medicines Agency database of suspected adverse reactions related to medicinal products in the European Economic Area (EudraVigilance), for fatal adverse events associated with treatment with alemtuzumab. Trygve Holmøy ...

Highlights from ECTRIMS

ECTRIMS 2019 | BestPractice | kl. 3:20 |

Melinda Magyari, Head of the Danish MS Registry, gives in this MEdtalk some of her highlights from the ECTRIMS ...

Patients with MS are often initially treated with moderately effective disease modifying therapies, and in case of insufficient treatment response therapy is escalated to high efficacy disease modifying therapies. In this MEDtalk Mathias Due Buron present Danish data for difference of disease activity in patients started initially on high efficacy disease modifying therapies compared to ...

A larger decrease in total costs was observed in patients with MS who received their first disease modifying therapies early, which could potentially be explained by a slower disease progression leading to maintained work ...

Galina Zheleznyakova have dentified a number of different sncRNAs where further research may pave the way for identification of informative biomarkers and possible treatment targets. In this MEdtalk she present the result from the ...

#Senaste tidskrift

Diabetes / Hjärta-kärl/ Lungmedicin

Nr. 34 • september 2019
Årgång 9
  • KOL
  • Kronisk hosta
  • LDL-kolesterol